Investors

Date	Name	Title	Type	Shares Traded	Price Range
Jan 8, 2013	vagelos p roy	Officer	Disposition (Non Open Market)	1,254	n/a
Apr 4, 2013	vagelos p roy	Officer	Disposition (Non Open Market)	1,215	n/a
Dec 17, 2007	yancopoulos george	Officer	Acquisition (Non Open Market)	500,000	n/a
Jun 27, 2012	yancopoulos george	Officer	Acquisition (Non Open Market)	500,000	n/a
Aug 20, 2008	roberts william	Officer	Option Execute	34,840	6.50
Apr 27, 2009	roberts william	Officer	Option Execute	15,160	6.50
Dec 15, 2008	goldberg murray a	Officer	Option Execute	1,700	7.41
Jan 2, 2009	goldberg murray a	Officer	Option Execute	1,300	7.41
Sep 29, 2008	schleifer leonard s	Officer	Option Execute	73,010	7.41
Dec 19, 2008	vagelos p roy	Director	Option Execute	130,000	7.41
Dec 16, 2008	yancopoulos george	Officer	Option Execute	100,000	7.41
Feb 20, 2009	baker charles a	Director	Option Execute	10,000	7.66
Feb 23, 2009	brown michael s	Director	Option Execute	5,000	7.66
Sep 9, 2008	brown michael s	Director	Option Execute	5,000	7.66
Jan 21, 2009	gilman alfred g	Director	Option Execute	10,000	7.66
Nov 5, 2007	goldstein joseph l	Director	Option Execute	4,200	7.66
Nov 5, 2007	goldstein joseph l	Director	Option Execute	800	7.66
Jan 22, 2008	goldstein joseph l	Director	Option Execute	5,000	7.66
Oct 2, 2007	shooter eric m	Director	Option Execute	10,000	7.66
Feb 15, 2008	baker charles a	Director	Option Execute	10,000	7.91
Showing 101-120 of 639 transactions Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32  See Previous 20 | See Next 20

Stock transaction information provided by EDGAR Online. Regeneron Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.